Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Survey Reveals Importance of Precise PV Treatment Guidelines and Research

March 13th 2023

Heterogeneous patterns of polycythemia vera management indicate the need for continued research in this disease and increased guideline specificity across treatment centers in Italy.

FDA Receives Type A Meeting Request for Synthetic Hypericin in Early-stage Cutaneous T-cell Lymphoma

March 13th 2023

Soligenix has submitted a Type A meeting request to the FDA to discuss the contents of a refusal to file letter from the regulatory agency regarding the new drug application for synthetic hypericin for the treatment of early-stage cutaneous T-cell lymphoma.

Summary of Unmet Needs and Future Directions in MDS

March 9th 2023

Experts close by summarizing key advances and remaining unmet needs across all MDS risk groups, and share their hopes for the future.

MDS/MPN-RS-T Overlap Syndromes

March 9th 2023

A brief discussion centered on MDS/MPN-RS-T overlap syndromes, considerations for diagnosis, available treatment options, and updates in the space.

FDA Accepts BLA Resubmission for Remestemcel-L in Pediatric Steroid-Refractory aGVHD

March 8th 2023

The FDA’s Office of Therapeutic Products has accepted a resubmission of the biologics license application (BLA) for remestemcel-L for the treatment of pediatric patients with steroid-refractory, acute graft-vs-host-disease.

New Generation of TKIs Challenge Standards of Care in Newly Diagnosed Ph+ ALL

March 7th 2023

The advent of effective first-generation TKIs has allowed for improvements among patients with Philadelphia chromosome–positive disease, which is traditionally associated with a poor prognosis, as it generally does not respond to conventional chemotherapy options.

EU Approves Luspatercept for Anemia in Patients with Non–Transfusion-Dependent Beta Thalassemia

March 7th 2023

The European Commission has granted a full marketing authorization to luspatercept-aamt for use in adult patients with anemia associated with non–transfusion-dependent β-thalassemia.

Treatment Strategies in Patients With Relapsed/Refractory AML

March 7th 2023

Centering its discussion on relapsed/refractory acute myeloid leukemia, the panel highlights broader treatment strategies in this setting.

Role of Stem Cell Transplant in Acute Myeloid Leukemia

March 7th 2023

Before closing out their discussion on first-line treatment options for patients with AML, expert oncologists reflect on the role of stem cell transplant in AML.

Recent Data Updates in Higher-Risk MDS

March 2nd 2023

The panelists touch on emerging data in the higher-risk MDS space, including updates presented at ASH 2022.

Higher-Risk MDS: First- and Second-Line Therapies and Case 3 Presentation/Discussion

March 2nd 2023

The panel turns their focus to higher-risk MDS, starting with a discussion of first- and second-line treatment options, followed by a third and final case presentation and discussion led by Dr Platzbecker.

Dr. Chen on the Efficacy of Vedolizumab Prophylaxis for aGVHD in the GRAPHITE Trial

March 1st 2023

Yi-Bin Chen, MD, discusses key data on the use of vedolizumab in lower gastrointestinal acute Graft-Versus-Host Disease according to the phase 3 GRAPHITE study.

Dr. Muffly on the Evaluation of Briquilimab Conditioning Prior to HSCT in AML

February 28th 2023

Lori Muffly, MD, discusses the clinical outcomes with the use of a novel conditioning regimen featuring the anti-CD117 monoclonal antibody briquilimab plus low-dose irradiation and fludarabine prior to allogeneic hemopoietic stem cell transplant in older patients with acute myeloid leukemia.

Dr. Fingrut on the Association Between Ancestry, Socioeconomic Status, and HLA-Disparate Grafts

February 28th 2023

Warren Fingrut, MD, discusses the association between non-European ancestry and low socioeconomic status with the receipt of HLA-disparate grafts.

Dr. Kurtzberg on Long-term OS for Remestemcel-L in Pediatric Steroid-Refractory aGVHD

February 28th 2023

Joanne Kurtzberg, MD, discusses the long-term survival outcomes from an observational cohort study evaluating remestemcel-L in pediatric patients with steroid-refractory acute graft-vs-host disease.

Resistance Mutations Present an Ongoing Challenge in Aggressive Hematologic Malignancies

February 28th 2023

With acquired resistance patterns emerging for nearly every agent, hematologic experts are looking closely at sequencing patterns, but more work needs to be done in aggressive malignancies in which mutations associated with resistance may be present before therapy even begins.

Novel Venetoclax-Based Regimens in Patients With AML Unfit for Intensive Chemotherapy

February 28th 2023

A comprehensive review of novel venetoclax-based combination therapy in patients unfit for intensive chemotherapy who are diagnosed with AML.

Frontline Treatment in Patients With IDH-Mutated AML Unfit for Intensive Chemotherapy

February 28th 2023

In the setting of IDH-mutated AML, panelists consider optimal treatment options in patients unfit for intensive chemotherapy.

Practical Advice on the Management of Tumor Lysis Syndrome

February 28th 2023

Closing out his discussion on tumor lysis syndrome, Anthony Perissinotti, PharmD, BCOP, shares practical advice on its identification and management.

New Approvals Continue to Shift Treatment Landscape in Hematologic Malignancies

February 27th 2023

Kathryn Maples, PharmD, BCOP, discusses recent approvals, updated labeling, and drug removals across leukemia, lymphoma, and multiple myeloma.